Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01393899 · ClinicalTrials.gov registry record · Phase 2
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Phase 2 study of Crohn's Disease, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT01393899 is a Phase 2 study of Crohn's Disease that has completed, run by Pfizer. The registered enrollment target is 180 participants, below the 2,393-participant average among 105 other Crohn's Disease trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT01393899, a Phase 2 study of Crohn's Disease, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease who completed the double-blind induction treatment in Study A3921083 and achieved clinical response-100 and/or clinical remission (CDAI\<150) at Week 8.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CP-690,550
Study Locations (20)
Florida
- Gasteroenterology Consultants of Clearwater - Clearwater
- West Coast Endoscopy Center - Clearwater
- Clinical Research of West Florida, Inc. - Clearwater
- Shands Endoscopy Center - Gainesville
- Shands Hospital at the University of Florida - Gainesville
- Shands Medical Plaza and Cancer Center - Gainesville
- University of Florida - College of Medicine - Gainsville
- Gastroenterology Group of Naples - Naples
- Gulfshore Endoscopy Center (Endoscopies Only) - Naples
- North Florida Gastroenterology Research, LLC - Orange Park
- Internal Medicine Specialists - Orlando
California
- ACMG Endoscopy Center - Anaheim
- ACRI - Phase I, LLC - Anaheim
- Advanced Clinical Research Institute-Phase 1, LLC - Anaheim
- West Coast Clinical Trials - Cypress
- Alliance Clinical Research - Oceanside
Colorado
- Clinical Research Of The Rockies - Lafayette
Georgia
- Gastroenterology Associates of Central Georgia, LLC - Macon
Kansas
- Cotton-O'Neil Clinical Research Center, Digestive Health - Topeka
Maryland
- Chevy Chase Endoscopy Center - Chevy Chase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2012-03 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01393899
The ClinicalTrials.gov registry entry for NCT01393899 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,393-participant average among 105 other Crohn's Disease trials with a reported enrollment target (92% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01393899 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT01393899 about?
NCT01393899 is a clinical study titled "The Safety And Efficacy Of Maintenance Therapy With CP-690,550". This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease who completed the double-blind induction treatment in Study A3921083 and achieved clinical response-100 and/or clinical remission (CDAI\<150) at Week 8.
What is the current status of trial NCT01393899?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2012-03. Estimated completion is 2015-07.
What conditions does trial NCT01393899 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT01393899?
The interventions under investigation include: Placebo (DRUG), CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT01393899?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01393899 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
RECRUITING · Phase 2
-
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.